Which approach is NOT recommended for influenza chemoprophylaxis?

The use of dual antiviral agents for influenza chemoprophylaxis is not recommended due to the potential for increased risk of adverse effects and the emergence of resistance. Current guidelines typically advocate for using a single antiviral agent, as this approach effectively reduces the risk of complications and helps to limit the development of resistant viral strains. Combination therapy may not provide additional benefits and could complicate treatment regimens unnecessarily.

In contrast, postexposure prophylaxis for high-risk individuals and pre-exposure prophylaxis for vulnerable patients are recognized as effective measures to prevent influenza in those who are at increased risk of severe complications. Additionally, consulting to switch medications if symptoms develop is an important practice to ensure appropriate treatment is provided efficiently and effectively, aligning with clinical guidelines.